All News
Filter News
Found 808,679 articles
-
Global Cannabis Market set to Grow as Multinational Companies Eye Entry
10/2/2018
According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023 while growing at a CAGR of 37% during the forecasted period.
-
Optima Healthcare Acquires Vantage Clinical Solutions
10/2/2018
Optima Healthcare Solutions, a leading provider of cloud-based solutions for post-acute care providers, today announced the acquisition of Vantage Clinical Solutions, Inc., a company that specializes in revenue cycle management (RCM) and digital marketing services for physical therapy practices.
-
Rite Aid Honoring its Pharmacy Champions During American Pharmacists Month
10/2/2018
Customers can win $2,500 in Rite Aid Gift Cards by Recognizing Rite Aid Pharmacists, Pharmacy Technicians and Wellness Ambassadors for Outstanding Service and Care
-
GB Sciences' Drug Development Program Benefits from Establishment of Clear Pathway for Cannabis-Based Drug Approvals and Commercialization
10/2/2018
DEA rescheduling of Epidiolex to Schedule V establishes commercial viability for cannabis-based formulations
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cocrystal Pharma, Inc. f/k/a BioZone - COCP
10/2/2018
Pomerantz LLP is investigating claims on behalf of investors of Cocrystal Pharma, Inc.
-
Click Therapeutics Expands Executive Team with Chief Medical Officer and Chief Strategy Officer
10/2/2018
Dr. Randall Kaye and Austin Speier Join Executive Team
-
Lewy Body Dementia is a Life-Shortening, Terminal Diagnosis
10/2/2018
It was with great sadness that the Lewy Body Dementia Association (LBDA) learned of Ted Turner's diagnosis of Lewy body dementia (LBD). Mr. Turner's announcement highlights the growing tide of diagnoses of this confusing but common, and relentlessly progressive, disorder.
-
ROTH Capital Partners to Host ROTH Battle of the NASH Thrones Investor Conference in New York City on October 17th, 2018
10/2/2018
ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Battle of the NASH Thrones Investor Conference on Wednesday, October 17, 2018 at the Park Hyatt Hotel in New York City.
-
Thermo Fisher Scientific Announces Sixth Licensing Agreement for B•R•A•H•M•S PCT
10/2/2018
Thermo Fisher Scientific Inc., today announced the sixth licensing agreement for its B·R·A·H·M·S PCT (procalcitonin) biomarker that provides information on the presence and severity of bacterial infections.
-
Cardax Launches Human Clinical Trial Targeting Cardiovascular Inflammatory Health
10/2/2018
Cardax, Inc. has launched its Cardiovascular Health Astaxanthin Supplement Evaluation clinical trial targeting cardiovascular inflammatory health.
-
Exagen Featured in Eight Scientific Presentations at The 2018 ACR/ARHP Annual Meeting in Chicago, ILLeading immunology laboratory continues strides with first ever economic impact data for AVISE Lupus
10/2/2018
2018 ACR/ARHP Annual Meeting being held in Chicago, IL, October 19 - 24
-
Teligent, Inc. Announces FDA Approval of Fluocinonide Ointment USP, 0.05%
10/2/2018
Teligent (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the Food and Drug Administration (FDA) of Fluocinonide Ointment USP, 0.05%.
-
Puma Biotechnology’s Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China
10/2/2018
NERLYNX was approved in the United States for the same indication in July 2017 and in the European Union for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in September 2018.
-
COCRYSTAL LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cocrystal Pharma, Inc. To Contact The Firm
10/2/2018
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cocrystal Pharma, Inc.
-
GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment
10/2/2018
GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.
-
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions
10/2/2018
Mesoblast Limited today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has been selected as a late-breaking presentation at the 2018 Scientific Sessions of the American Heart Association being held in Chicago from November 11-13.
-
SELLAS to Present Data from Phase 2b Trial of NeuVax + Herceptin® at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/2/2018
SELLAS Life Sciences Group, Inc. today announced that data from the Phase 2b trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) for the treatment of women with triple-negative breast cancer (TNBC) will be presented in a poster presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 9-11, 2018 in Washington, D.C.
-
Arbutus to Present at Chardan’s Genetic Medicines Conference
10/2/2018
Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 2:45 pm – 3:10 pm ET in New York.
-
Trident Brands Inc. Subsidiary Brain Armor Receives Health Canada Approval to Sell and Distribute in Canada
10/2/2018
Health Canada has granted Brain Armor an NHP License for their premium line of brain health supplements
-
Expanded Certification Program Provides More Opportunity for Medical Professionals to Practice Functional Medicine
10/2/2018
The Institute for Functional Medicine (IFM) today announced an expansion to its certification program; allowing a broader range of medical professionals to have the opportunity to integrate Functional Medicine into their practice.